Sino Biopharmaceutical completes enrollment of the first patient in phase III study of tecotabart vedotin for GC/GEJC adenocarcinoma (HK$6.17, 0.00)
Sino Biopharmaceutical enrolls first patient in US Phase II trial of Kylo-11 "LPA siRNA" in patients with ASCVD and elevated lipoprotein (a) (Lp(a)) (HK$5.96, 0.00)
Chia Tai Tianqing Pharmaceutical Group receives approval for IND application from FDA for TQB3205 for treatment of advanced malignant tumor (HK$6.04, 0.00)
StreetAccount Sector Summary - China Healthcare March Recap
Akeso Inc reports updated results on Cadonilimab combination therapy in PD-(L)1 inhibitor-resistant advanced NSCLC at ELCC 2026 (HK$140.50, 0.00)
Sino Biopharmaceutical completes acquisition of Hygieia; deal was announced on 13-Jan (HK$5.85, 0.00)
StreetAccount Metrics Recap - Sino Biopharmaceutical FY Earnings (HK$5.82, 0.00)
Sino Biopharmaceutical reports FY underlying profit attributable CNY4.54B vs StreetAccount CNY4.89B (HK$5.82, 0.00)
StreetAccount Consensus Metrics Preview - Sino Biopharmaceutical FY Earnings
Sino Biopharmaceutical receives NMPA clinical trial approval for TRD221 for treatment of osteoarthritis (HK$6.05, 0.00)
Powered by FactSet Research Systems Inc.